TGA proposed changes to the biologics regulatory framework
Posted 6 years ago
These changes will aim to improve patient protection from providers of unproven therapies and ensure patients have access to safe and effective new therapies. Changes will also include a prohibition on advertising autologous HCT products to patients, and a requirement to report adverse events.
For more information, visit the TGA website.